By Sumatee Nakarmi
People suffering from Alzheimer’s disease, a brain disorder that causes memory loss and cognitive difficulties, are finding hope thanks to a new medication called Donanemab (also marketed as Kisunla). Donanemab was authorised on 23rd October 2024, by the Medicines and Healthcare Products Regulatory Agency (MHRA). Scientists have discovered that this medication can slow down the disease, particularly when treatment begins early. However, because of the uncertainty around the cost and delivery, the NHS does not promote this treatment.
What Is Alzheimer’s?
Alzheimer’s is a disease that mostly affects elderly people. It causes changes in the brain, and over time these changes can lead to memory problems, confusion and difficulty doing everyday tasks. Unfortunately, there is currently no cure for Alzheimer’s, however, Donanemab is a large step towards a better treatment.
How Does Donanemab Work?
Donanemab is a medicine that helps the body clear out the harmful amyloid plaques (misfolded proteins that form between nerve cells) from the brain. In a study of more than 1,700 patients, scientists found that Donanemab slowed the disease by about 35% in people who started taking it early. This means it could give people more time before their memory and thinking skills get worse. The drug is given through an IV (a small tube in your arm), and patients need regular check-ups to make sure it is working safely.
Why Is This Important?
Alzheimer’s affects millions of families around the world. It can be heartbreaking to see a loved one struggle with memory and communication. While Donanemab is not a cure, it offers hope that people could have more time to enjoy life and stay connected with their family and friends.
What Are The Risks?
Donanemab still carries potential risks, much like many new medications. Some participants in the research had mild side effects, such as brain swelling or minor bleeding. To ensure the drug’s safety, doctors have studied it closely and continue to do so.
The Future Of Alzheimer’s Treatment
The potential implications of Donanemab for the future have scientists intrigued. It demonstrates that addressing the underlying causes of Alzheimer’s, such as amyloid plaques, can have an impact. Scientists are looking for more methods to prevent or stop the disease.
Donanemab gives us hope for the time being. Families may have more time to make memories together if they receive early diagnosis and treatment. This discovery is a reminder of the value science and research have in overcoming difficult conditions.